Roidipedia.Compound reference & reporting
06 AUG 2026
CompoundsResearch chemical 4-HO-MiPT (Miprocin)
Research chemicalResearch chemicalPsychedelicTryptamine

4-HO-MiPT (Miprocin)

Also known as Miprocin · 4-hydroxy-N-methyl-N-isopropyltryptamine

4-HO-MiPT (4-hydroxy-N-methyl-N-isopropyltryptamine, Miprocin) is a synthetic psilocin-analogue psychedelic tryptamine described by Shulgin. It is taken non-medically for visual and entheogenic effects. Human evidence is anecdotal; potency and safety are not established, and individual dose responses differ markedly.

01 Overview

4-HO-MiPT is a 4-hydroxytryptamine related to psilocin, differing by an N-isopropyl substitution. Users describe a bright, stimulating psychedelic state with strong visuals and comparatively clear headspace, and a moderate duration. It is sold as a research chemical in jurisdictions where classical psychedelics are controlled.

No controlled human studies exist; all effect and dose information comes from self-experiment reports and harm-reduction sources. Reported potency is high (active in low-milligram amounts), so accurate weighing matters and dose responses vary widely between people. Serotonergic psychedelics carry a risk of acute psychological distress and, rarely, prolonged perceptual disturbances.

02 Mechanism

Serotonin 5-HT2A receptor agonist/partial agonist, the classical psychedelic mechanism, with activity at additional serotonin receptor subtypes.

03 Dosing

TierDoseRouteNotes
Threshold5–10 mgOralApproximate; from user reports.
Common15–25 mgOralOnset ~20-40 min, duration ~4-6 h. Not clinically validated.
Strong25–35 mgOralOverwhelming effects more likely.

04 Effects

EffectMagnitudeEvidence
Visual effectsPronounced open- and closed-eye visuals, colour and geometry enhancement reported by users.Anecdotal
Stimulation and euphoriaEnergetic, mood-lifting quality is a commonly noted feature.Anecdotal
Altered thought and perceptionChanges in cognition, time sense and self-perception typical of psychedelics.Anecdotal

05 Side effects

EffectSeverityFrequencyEvidenceCountermeasures
Stimulation / insomniaRestlessness and difficulty sleeping, reflecting the stimulating character.MildCommonAnecdotal
Cardiovascular stimulationIncreased heart rate and blood pressure.MildCommonAnecdotal
Anxiety and challenging experiencesFear, confusion or panic, more likely at high doses or in poor setting.ModerateCommon at higher dosesAnecdotal

07 References

TiHKAL: The ContinuationShulgin & Shulgin, 1997
New psychoactive substances monitoringEUDA (formerly EMCDDA)

08 Discussion0 comments

?
Sign in to add a comment…
Create account
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.